Ideally, in their view, Trump’s FDA would ban the drug altogether — though such a move would be sure to spark legal action ... On Sunday, the FDA approved Biogen and Eisai’s application ...

The drug made $1.7 billion for Biogen last year and is its most important ... Zolgensma is only the second gene therapy to be approved in the US after Spark’s Luxturna for a rare eye disease.

Former MRC Technology drug Tysabri (natalizumab) eventually ended up as Biogen’s drug for multiple ... but prices have been sky high, such as Spark Therapeutics’ Luxturna (voretigene ...

The ClearBridge Global Value Improvers Strategy outperformed its MSCI World Value benchmark during Q4 2024. Click here to ...

Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Tecno has launched a new variant for its affordable Spark 30C 5G smartphone in India. The company will now be offering an 8GB memory variant, which offers double the memory of the previous 4GB ...

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.

Overall, Biogen’s fourth-quarter revenues clocked in at $2.46 billion, coming in above Wall Street’s estimate of $2.41 million. Full-year revenues declined 2% over 2023 to $9.7 billion, which ...